

## IMPORTANT NEW DEVELOPMENTS IN HORMONE REPLACEMENT THERAPY

### **BODY-IDENTICAL HRT - MICRONISED PROGESTERONE IS FINALLY AVAILABLE IN AUSTRALIA**

Dr John Eden

Practical points:

- The lack of quality control and testing has led the International Menopause Society to instruct their members not to use hand-made, compounded HRT in the form of troches, creams and pessaries.
- Oral (including troche) DHEA appears to have no role in the management of menopausal women and should not be including in a body-identical HRT regimen.
- Progestins negate much of the cardiovascular benefits of oestrogens and appear to be the HRT component linked to the slightly increased risk of breast cancer.
- Body-identical hormones are exact duplicates of the human hormones.
- Micronised progesterone is superior to progestins in terms of safety profile and side-effects and may reduce hot flushes when used alone; it may be combined with systemic oestrogen.

Introduction

Even though menopause is a normal physiological condition, for some women the consequences are devastating. Approximately half of all Australian women will have no or mild hot flushes when they become menopausal. However, around a quarter of women will have severe debilitating symptoms that cause fatigue, mood swings, difficulty concentrating at work and disrupted sleep. They may suffer loss of sexual desire that can contribute to relationship problems. Many of these women are not being treated for these problems, perhaps because they are not aware of the many options available, or because of fear of hormone replacement therapy (HRT).

This lack of effective management of menopausal symptoms was borne out in a recent publication by Professor Sue Davis' group in Melbourne.<sup>1</sup> They found that 29% of postmenopausal women under fifty-five years of age were having severe vasomotor symptoms, and these were also occurring in 15% of postmenopausal women aged fifty-five to fifty-nine years and 6.5% of women aged sixty to sixty-

---

nine years of age. The use of hormone replacement therapy (HRT), vaginal oestrogens and non-hormonal therapies for flushing (e.g. selective serotonin reuptake inhibitors) were “strikingly low, suggesting that menopause remains an undertreated condition.” Many couples are putting up with painful sex, or have given up on sex, despite the fact that topical oestrogens are effective, safe, cheap, and have been available for decades.

There are long-term consequences of menopause too, especially for those whose menopause occurs early (under forty years of age). These younger menopausal women, if untreated, are at increased risk of heart disease, osteoporosis, affective disorders and dementia.<sup>2</sup>

### Don't All Hormone Replacement Therapies Increase Breast Cancer Risk?

Any practitioner who treats menopausal women knows that there is much fear around the use of HRT and that this is mostly linked to the risk of breast cancer. This fear started on the 10th of July 2002, when the Women's Health Initiative (WHI) Study released their preliminary results to the world media. It was stated that there was a 26% increased risk of breast cancer amongst those subjects who took conjugated oestrogens with medroxyprogesterone acetate (CEE-MPA).<sup>3</sup> In Australia, the headlines read “Stop your HRT and see your doctor” (e.g. Daily Telegraphy 10th of July, 2002). This was widely interpreted by women as stating that HRT usage is linked to a one in four risk of breast cancer. It is well known amongst communication experts that unless a person is trained in statistics, percentages are commonly misunderstood. In fact, the increased risk of breast cancer was only seen after five years of conjugated equine oestrogens (CEE) and medroxyprogesterone acetate (MPA) use and the absolute risk was eight per 10,000 women per year.<sup>3</sup> There were also eight other types of cancer prevented by the same HRT, (two fewer endometrial cancers and six fewer bowel cancers per 10,000 women per year), but this was not widely reported.<sup>3</sup>

There is now a widely held view that all HRT regimens are the same and that all of them increase breast cancer risk. Sadly, women many women do not know that in the same study, those using CEE alone (hysterectomised patients) had a significantly decreased risk of breast cancer. Also, it is not well known that other HRTs, such as tibolone, are also associated with a decreased risk of breast cancer (LIFT study).<sup>4</sup>

### "I Want to Use Natural Hormones"

Over the last few decades, women themselves have expressed an interest in using "natural hormones." Many are taking hand-made, untested, compounded HRT in the form of troches, creams and pessaries. These products typically contain oestradiol (E2), and other oestrogens, progesterone, DHEA and often other human hormones. These are typically called "bio-identical HRT" by their proponents. This topic has been reviewed by Cirigliano.<sup>5</sup> The lack of quality control and testing has led the International Menopause Society to instruct their members not to use such products.<sup>6</sup>

In Australia, we have had access to pharmaceutical grade E2 as tablets, patches, gels and vaginal products for decades. Oestriol (E3) is also available as tablets, pessaries and vaginal cream. Testosterone has been available as a cream (Lawley Pharmaceuticals; private script only). However, until recently, Australian women and their health practitioners have not had access to pharmaceutical-grade progesterone. As such, synthetic progestins have been used to protect the endometrium from the stimulatory effects of E2. They are very effective, but around one woman in eight develops side-effects similar to premenstrual tension, such as mood swings, feeling flat, depression, and bloating. Also, progestins negate much of the cardiovascular benefits of oestrogens and appear to be the HRT component linked to the slightly increased risk of breast cancer.

In brief, micronised progesterone is superior to progestins in terms of safety profile and side-effects. The Europeans, especially the French, have published widely on the use of micronised progesterone (mP4) taken orally or vaginally, with E2 tablets, patches or gel. Micronisation is an industrial process that produces a substance which has similar sized very small particles that result in better absorption. In brief, mP4 is superior to progestins in terms of safety profile and side-effects. For the first time in Australia, mP4 is now available as a pharmaceutical product. In the author's opinion, this will allow a "re-telling" of the HRT story and permit Australian women and their doctors to have access to tested, safe, effective and truly "natural" HRT.

We have seen this evolution from biologicals / synthetics to the body-identical hormones in other areas of medicine too. Decades ago, insulin was extracted from the pancreases of animals such as cows or pigs. It worked, but there were problems, such as allergic reactions and tolerance. Once human insulins became available, we moved on from using the animal-derived products. Growth

---

hormone and follicle stimulating hormone were also originally extracted from biological sources; now the human hormones are used and they are much safer.

Guidelines for the usage of HRT have changed over the years and recently the International Menopause Society has published an excellent document reviewing the evidence base for the treatment of menopause.<sup>6</sup> The following is a link to this article, however registration and payment is first required: <http://dx.doi.org/10.3109/13697137.2015.1129166>

#### Body-Identical Hormone Replacement Therapy

Professor Nick Panay points out that the term "bio-identical hormones" is rather imprecise and is really a marketing term.<sup>7</sup> Bio-identical hormones are exact duplicates of the human hormones (such as E2, progesterone, testosterone). As previously mentioned, the term, "bio-identical hormones," is almost exclusively used by the compounding industry, which at the moment escapes the intense quality control, safety and efficacy testing demanded by the regulatory bodies for pharmaceuticals. In his paper, Professor Panay makes several points worth quoting directly:

"Compounding pharmacies market their own unregulated bio-identical products promoted in a number of countries by high-profile celebrities. Some practitioners prescribing these compounded preparations claim to be able to calculate the precise level of each deficiency from salivary hormones and then replace the precise amount using estrogen, progesterone and testosterone delivered by lozenges or creams. This practice is not supported by evidenced for efficacy nor safety."

Thus, body-identical HRT might be seen as pharmaceutical-grade, "bio-identical HRT." However, Professor Panay points out that "bios" in Greek means "life", and so he has coined the term "body-identical HRT," as a more accurate term to cover the prescribing of pharmaceutical grade human hormones such as progesterone and E2.

Body identical sex hormones are typically derived from plant sources, such as soya or wild yam. Chemicals such as diosogen are extracted then converted in a laboratory into the various hormones. What is produced is identical to the human hormone.

Professor Panay goes on to make an interesting comment about the WHI Study and the differences between synthetic HRT and body-identical HRT:

"The adverse outcomes seen in the Women's Health Initiative (WHI) were mainly due to an over-dosage of hormones in a relatively elderly population. However, fundamental differences exist between conjugated equine estrogens and 17-beta estradiol and between medroxyprogesterone

acetate and natural progesterone. It is likely that these differences also contributed to the adverse outcomes in WHI, which were contrary to the cardiovascular benefits seen in previous observational studies.”<sup>7</sup>

For the rest of this article, the term “body-identical HRT” will be used. I will briefly discuss E2, DHEA and testosterone, but my main focus will be on the new product, mP4, 100mg and 200mg.

	Body-Identical HRT	Bio-identical HRT
Quality of product:	Pharmaceutical grade (highest quality)	Compounded (unknown quality)
Safety:	Known, tested in controlled trial	Unknown
Efficacy:	Superior to placebo	Unknown
Identical to human hormones:	Yes	Likely

## Oestradiol

Oestradiol was originally discovered in 1935 and is now available as tablets, patches, gel and a vaginal tablet. For most healthy women under sixty years of age, oral E2 is safe. However, oral E2 does undergo first-pass liver metabolism. This can be a positive effect (such as lowering total and low density lipoprotein cholesterol levels) or a negative effect (such as activating hepatic proteins such as the clotting factors, sex-hormone binding globulin [SHBG]).<sup>7,8</sup> Thrombosis risk (deep venous thrombosis, pulmonary embolism, stroke) increases steadily with age and all the oral HRTs are associated with increased risk of thrombosis in older women (over sixty to sixty-five years of age).<sup>3,4,8</sup> Those with risk factors such as obesity, thrombophilia, or past history of thrombosis should avoid oral

---

oestradiol. In contrast, transdermal oestradiol (patches, gels) appears to have minimal or no increased risk of thrombosis.<sup>8</sup>

Vaginal E2 should not be inserted deep into the vagina but rather delivered to the anterior vaginal wall. From a pharmacokinetic perspective, the vagina has two compartments. The posterior component has vascular and lymphatic connections with the uterus and so E2 placed in the posterior vagina, if used for long periods of time, could theoretically induce endometrial hyperplasia. The anterior compartment has connections with the urethra, clitoris and bladder<sup>9</sup> and so placement of E2 in this region best reduces atrophic symptoms.

### Testosterone

The topic of testosterone replacement for women may be reviewed in detail elsewhere.<sup>10-12</sup> In summary, a woman with fatigue and loss of sex drive and who has a low total or free testosterone (the lower half of the normal range) may be considered for testosterone replacement.<sup>10-12</sup> Clearly, other causes of her presentation need to be excluded (such as iron deficiency, thyroid disease, hormonal contraception, relationship issues). The only pharmaceutical-grade testosterone product available in Australia is AndroFeme® 1% (Lawley Pharmaceuticals). The usual dose is 0.5 to 1.0mL of cream rubbed into the thigh daily, aiming to achieve a free androgen index (FAI) between 4% and 7%. Approximately two-thirds of women will find that energy levels and sexual desire will improve over three to six months.<sup>12</sup>

If E2 is given concomitantly with testosterone, then the transdermal route is preferable as oral E2 may increase SHBG levels (SHBG is a liver protein). High SHBG levels will result in a very low FAI and low free testosterone levels. Used appropriately, to date, no significant safety issues have been found with long-term use of testosterone replacement in women.<sup>10-12</sup>

### Dehydroepiandrosterone

Dehydroepiandrosterone (DHEA) has been promoted (especially on the Internet) as an "anti-ageing" hormone. It is the most abundant steroid in blood and levels fall with age. However, there is no receptor for DHEA in the human body. It can be inter-converted into oestrogens and androgens in tissues with the suitable enzyme systems (e.g. the vagina). There have been a number of randomised trials of DHEA and these have been reviewed.<sup>13</sup> In summary, there appears to be no therapeutic effect through giving systemic DHEA to menopausal women. Topical low-dose DHEA (6.5mg daily) applied

---

to the vaginal epithelium does result in oestrogenic effects, with no measurable circulatory levels of oestrogenic or androgenic steroids.<sup>14</sup>

Oral (including troche) DHEA appears to have no role in the management of menopausal women and should not be including in a body-identical HRT regimen.

### Progesterone

Micronised progesterone is available in Australia from the 1st September 2016 as Prometrium<sup>®</sup>, (100mg) and Utrogestan<sup>®</sup>, (200mg) gelatin caps.

In broad terms, progesterone is a relatively difficult hormone to deliver to the human body (in contrast to oestrogens, which are readily absorbed via mouth, nose, and skin). Micronisation of the particles greatly enhances absorption of progesterone. The PEPI Study<sup>15</sup> was a three-year study examining a number of safety endpoints for CEE (0.625mg), given with a variety of progestins. The Study demonstrated that the administration of oral mP4 (200mg) for twelve days per month effectively protected the endometrium against the stimulatory effects of CEE. Cuadros' group performed a ten-year study and showed that oral mP4 (100mg) taken daily with a 50ug E2 patch protected the endometrium and did not attenuate the cardiovascular benefits of the E2.<sup>16</sup>

Cicinelli<sup>9</sup> has reviewed the intravaginal delivery of E2 and mP4. The posterior vagina appears to be an excellent delivery site for mP4. In vitro fertilisation physicians have been using pessaries of mP4 to maintain pregnancies for years. Cincelli<sup>17</sup> performed a three-year study of thirty women who used E2 gel (Sandrena<sup>®</sup> gel) daily and mP4 100mg vaginally alternate daily. All developed endometrial atrophy on biopsy and amenorrhoea was achieved in 93% of cycles. Fernandez-Murga and colleagues<sup>18</sup> monitored sixty-four menopausal women, each using a 25ug/day E2 patch with vaginal mP4 100mg twice a week (inserted on the day of patch change). The number of subjects with amenorrhoea at twelve months was 100%. Endometrial thickness remained reduced and an atrophic endometrium was obtained in seven women who were biopsied. Pharmaceutical grade progesterone pessaries are also available in Australia.

Stute and colleagues recently published a systematic review of the impact of mP4 on the endometrium. The results are summarized below<sup>19</sup>

Recommended dosage of mP4 for women using E2 orally or transdermally:

Oral route

Cyclical: 200mg mP4 for twelve to fourteen days per month

Continuous: 100mg mP4 daily

Vaginal route

Alternate day: 100mg mP4

Sequential: 45-100mg for at least 10 days a month

Minimal dose: 100mg twice a week (more research needed; endometrial monitoring may be required)

Transdermal route

Not recommended

#### Cardiovascular Effects of mP4

Oestrogens can improve the cardiovascular risk profile (e.g. by improving the lipoprotein profile and through direct vascular effects). Typically, synthetic progestins antagonise these benefits. Casanova has shown that mP4 does not alter the cardiovascular or metabolic effects of transdermal E2.<sup>20</sup>

#### Effects of mP4 on the Breast

The E3N-EPIC Study is a French prospective cohort study investigating cancer risk factors in nearly 100,000 women born between 1925 and 1950.<sup>21</sup> Since June 1990, subjects have filled in a two yearly questionnaire. The authors assessed breast cancer risk in 54,548 postmenopausal women who had never used HRT before entering into the study. There were 958 primary breast cancers detected over six years. The mean duration the subjects took HRT for was 2.8 years. The results are shown below. The breast cancer risk was higher for those exposed to synthetic progestins when compared to those using mP4 ( $p < 0.001$ ).<sup>21</sup>



Relative risk of breast cancer from the E3N-EPIC Study<sup>21</sup>

HRT used	Relative Risk (95%CI)
Oestrogen alone (mostly E2)	1.1 (0.8-1.6)
Oestrogen and progestin	1.4 (1.2-1.7)
Oestrogen and mP4	0.9 (0.7-1.2)

This observation was confirmed recently. Asi and colleagues published a meta-analysis comparing the breast cancer risk of women using oestrogen and mP4 with those using oestrogen and a synthetic progestin<sup>22</sup>. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years and follow up of 3 to 20 years. Progesterone-oestrogen usage was associated with a significantly lower breast cancer risk compared with progestin-oestrogen users (RR 0.67; 96%CI 0.55-0.81).

Campagnoli<sup>23</sup> has reviewed the epidemiological and laboratory data on breast cancer risk with synthetic progestins versus mP4. He concluded, "The balance of the in vivo evidence is that progesterone does not have a cancer-promoting effects on breast tissue." (p 104)<sup>23</sup>

#### Mood Effects of mP4

Progestins are responsible for most of the unwanted side effects of HRT. Approximately 10% of women have side-effects similar to premenstrual tension when taking progestins such as MPA.<sup>24</sup> It is always worthwhile for the clinician to ask a menopausal patient how they felt on hormonal contraception. If they felt moody and irritable on a levonorgesterol-containing contraceptive, then they are likely to dislike MPA or nortisterone too. Micronised progesterone is much better tolerated in these circumstances.<sup>24</sup> Interestingly, a very small number of women become moody and irritable when taking oral mP4 as well. This is believed to be due to some reduced hepatic metabolites of P4. In these cases, the vaginal route is preferred, as there is no hepatic first-pass metabolism occurring.

## The Use of mP4 Alone for Hot Flushes

It has been shown that 300mg of mP4 orally is superior to placebo for treatment of hot flushes<sup>25</sup> and may be useful for some patients in whom oestrogens may be relatively contraindicated.

## Discussion

Many menopausal women having significant symptoms will prefer body-identical HRT. However, there is still a role for the other menopausal therapies. A Mirena<sup>®</sup> intrauterine device can effectively control the menstrual problems associated with the menopause transition. For some, a cyclical E2 therapy such as Trisequens<sup>®</sup>, Zoely<sup>®</sup> or Femoston<sup>®</sup> for one to two years will be appropriate and safe. Tibolone is a simple, effective and safe therapy for some menopausal women under the age of sixty years. Vaginal oestrogens are highly effective and safe (if placed in the anterior vaginal compartment) for vulvovaginal dryness<sup>9</sup> and they can help prevent urinary tract infections.

Fifty years of research has clearly shown that not all HRTs are the same. The WHI Study has shown that CEE-MPA used for more than five years is associated with a slightly increased risk of breast cancer (eight extra cases per 10,000 women per year).<sup>3</sup> However, in the WHI Study, oestrogen alone used for ten years did not increase breast cancer risk (and may even lower it).<sup>3</sup> Tibolone usage reduces breast cancer risk.<sup>4</sup>

However, many menopausal women having severe symptoms want to use body-identical HRT. Transdermal E2 (patch or gel) with micronised progesterone appears to be a safe and effective therapy for many of our patients. Most will take mP4 as a 100mg capsule daily (or 200mg cyclically), but for a very small number who can't take tablets or who have side-effects with oral mP4, then the topical vaginal route is available.

### Why Body-Identical HRT Is Important

- Many patients want to use natural hormones rather than synthetic preparations.
- Body-identical HRT has fewer side-effects than many synthetic hormone regimens.
- Micronised progesterone used orally or vaginally has few side-effects compared to progestins.
- HRT regimens containing mP4 appear to have a lower risk of breast cancer than those using synthetic preparations.
- Micronised progesterone does not negate the cardiovascular benefits of oestrogen, unlike most progestins.

### Summary

	<b>Transdermal E2 with micronised progesterone</b>	<b>Oral CEE-MPA or oral E2 plus progestin</b>
Effectiveness for treating menopausal symptoms	Effective	Effective
<b>Impact on clotting system</b>	Similar to placebo	Small increased risk of deep venous thrombosis, stroke (especially in older women)
Breast cancer risk	Similar to placebo; lower than progestin-regimens	After five years' usage, eight extra cases per 10,000 per year
Cardiovascular system	No adverse impact. May lower cardiovascular risk in women under 60 years of age	MPA negates cardiovascular benefits of oestrogen

---

## Further reading

International Menopause Society: <http://dx.doi.org/10.3109/13697137.2015.1129166>

Sheriff K. *Hormone Therapy: Monitoring Effects and Side Effects in Hormone Therapy: A clinical Handbook*. Springer. Ed: Sheriff, 2013

Panay N. *Premature Ovarian Insufficiency: Hormonal Aspects and Long-term Health in Managing the Menopause 2015*. Cambridge Medicine Press. Eds: Panay N, Briggs P, Kovacs G

## References

1. Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. *Menopause: The Journal of the North American Menopause Society* 2015; 22 (7): 1-8
2. Panay N. *Premature ovarian insufficiency: hormonal aspects and long-term health in managing the menopause*. 2015. Cambridge Medicine Press. Eds: Panay N, Briggs P, Kovacs G: 215-222.
3. WHI Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. *JAMA* 2002; 288: 321-33.
4. Cummings, SR, Ettinger B, Delmas PD et al. The effects of Tibolone in older postmenopausal women. *N Engl J Med* 2008; 359: 697-708.
5. Cirigliano, M. Bioidentical Hormone Therapy: A Review of the Evidence. *Journal of Women's Health* 2007; 16(5): 600-31
6. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. To link to this article: <http://dx.doi.org/10.3109/13697137.2015.1129166>
7. Panay N. Body identical hormone replacement. *Post Reprod Health* June 2014 20: 69-72.
8. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. doi: 10.1136/bmj.39555.441944.BE
9. Cicinelli E. Intravaginal oestrogen and progestin administration: advantages and disadvantages 2007. *Best Practice and Research Clinical Obstetrics and Gynaecology*; 22(2): 391-405
10. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in menopausal women not taking estrogen therapy. *N Engl J Med* 2008;359: 2005-2017.
11. Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertility and Sterility* 2007; 88 (1): 1-17
12. Davis SR and Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. *J Sex Med* 12; 9: 1134-1148.
13. Eden, J A. DHEA replacement for postmenopausal women: placebo or panacea? *Climacteric : the journal of the International Menopause Society*, 2015; 18(4), pp.439-40

- 
14. Labrie F, Martela C, Bérubéa R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. *Journal of Steroid Biochemistry and Molecular Biology* 138 (2013) 359– 367
  15. Writing group for PEPI. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. *JAMA* 1996; 275: 370-5.
  16. Cuadros JL, Fernandez-Alonso AM, Chedraui P et al. Metabolic and hormonal parameters in postmenopausal women after transdermal oestradiol treatment, alone or in combination to micronized oral progesterone. *Gynae Endocrinol* 2011; 27(3): 156-162.
  17. Cicinelli E, de Zigler D, Alfonso R et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3 year pilot study. *Fertility and Sterility* 2005; 83(6): 1859-63
  18. Fernandez-Murga L, Hemenegildo C, Tarin JJ et al. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. *Climacteric* 2012; 15: 455-459.
  19. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. *Climacteric* 2016; 19(4): 316-28.
  20. Casanova G, Spritzer PM. Effects of micronized progesterone added top non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. *Lipids in Health and Disease* 2012; 11:133
  21. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. In *J Cancer* 2005; 114: 48-454.
  22. Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. *Systematic Reviews* 2016; 5:121-9
  23. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. *J Steroid Mole Biol* 2005; 96: 95-108
  24. Sheriff K. *Hormone Therapy: Monitoring Effects and Side Effects in Hormone Therapy: A clinical handbook*. Springer. Ed: Sheriff, 2013: 79-83
  25. Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment – effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. *Gynecol Endocrin* 2012; 28(S2): 7-11